Discontinuation of Lenalidomide in Patients with Transfusion-Dependent Low- and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5q): Sustained Remissions, but Not Cure

被引：0
|
作者：
Giagounidis, Aristoteles [1 ]
Goehring, Gudrun [2 ]
Haase, Sabine [1 ]
Aul, Carlo [3 ]
Schlegelberger, Brigitte [4 ]
Kuendgen, Andrea [5 ]
Herbst, Regina [6 ]
Ehninger, Gerhard [7 ]
Platzbecker, Uwe [8 ]
机构：
[1] St Johannes Hosp, Med Klin 2, Duisburg, Germany
[2] Hannover Med Sch, Inst Cell & Mol Pathol, D-3000 Hannover, Germany
[3] St Johannes Hosp, Med Clin 2, Duisburg, Germany
[4] Hannover Med Sch, Inst Cellular & Mol Pathol, D-3000 Hannover, Germany
[5] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[6] Klinikum Chemnitz, Clin Internal Med 3, Chemnitz, Germany
[7] Univ Hosp, Med Clin 1, Dresden, Germany
[8] Univ Hosp Dresden, Dresden, Germany
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1464 / 1465
页数：2
相关论文
共 50 条
  • [1] Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
    Garcia-Manero, Guillermo
    Diez-Campelo, Maria
    Vellenga, Edo
    Jacoby, Meagan A.
    Merchan, Brayan
    Breems, Dimitri
    Cortelezzi, Agostino
    Doronin, Vadim
    Gomez, Valle
    Beckers, Marielle
    Della Porta, Matteo Giovanni
    Varsos, Helen
    Xiu, Liang
    DeAngelis, Nikki
    Nnane, Ivo
    Rose, Esther
    van Eygen, Koen
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (04) : E111 - E114
  • [2] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality
    Harada, Hironori
    Watanabe, Mitsumasa
    Suzuki, Kenshi
    Yanagita, Soshi
    Suzuki, Takahiro
    Yoshida, Yataro
    Kimura, Akiro
    Tsudo, Mitsuru
    Matsuda, Akira
    Tohyama, Kaoru
    Taniwaki, Masafumi
    Takeshita, Kenichi
    Takatoku, Masaaki
    Ozawa, Keiya
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (03) : 353 - 360
  • [3] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality
    Hironori Harada
    Mitsumasa Watanabe
    Kenshi Suzuki
    Soshi Yanagita
    Takahiro Suzuki
    Yataro Yoshida
    Akiro Kimura
    Mitsuru Tsudo
    Akira Matsuda
    Kaoru Tohyama
    Masafumi Taniwaki
    Kenichi Takeshita
    Masaaki Takatoku
    Keiya Ozawa
    [J]. International Journal of Hematology, 2009, 90 : 353 - 360
  • [4] BONE MARROW CYTOKINE CHANGES DURING TREATMENT WITH LENALIDOMIDE IN LOW AND INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES WITH DEL(5Q)
    Oliva, N.
    Ronco, F.
    Cuzzola, M.
    Alimena, G.
    Morabito, F.
    Spiriti, M. A. Aloe
    Galimberti, S.
    Cortelezzi, A.
    Specchia, G.
    Poloni, A.
    Ghio, R.
    Breccia, M.
    Finelli, C.
    Iacopino, P.
    D'Errigo, Mg
    Lagana, C.
    Latagliata, R.
    Nobile, F.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 381 - 381
  • [5] Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence
    Oliva, Esther N.
    Lauseker, Michael
    Spiriti, Maria Antonietta Aloe
    Poloni, Antonella
    Cortelezzi, Agostino
    Palumbo, Giuseppe A.
    Balleari, Enrico
    Sanpaolo, Grazia
    Volpe, Antonio
    Ricco, Alessandra
    Ronco, Francesca
    Alati, Caterina
    D'Errigo, Maria Grazia
    Santacaterina, Irene
    Kuendgen, Andrea
    Germing, Ulrich
    Latagliata, Roberto
    [J]. CANCER MEDICINE, 2015, 4 (12): : 1789 - 1797
  • [6] Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q)
    Oliva, Esther Natalie
    Nobile, Francesco
    Ronco, Francesca
    Alati, Caterina
    Morabito, Fortunato
    Poloni, Antonella
    Cortelezzi, Agostino
    Spiriti, Maria Antonietta Aloe
    Ricco, Alessandra
    Volpe, Antonio
    Balleari, Enrico
    Sanpaolo, Grazia
    Breccia, Massimo
    Clissa, Cristina
    Alimena, Giuliana
    Latagliata, Roberto
    [J]. BLOOD, 2010, 116 (21) : 1205 - 1206
  • [7] A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Beyne-Rauzy, Odile
    Mufti, Ghulam
    Mittelman, Moshe
    Muus, Petra
    Boekhorst, Peter Te
    Sanz, Guillermo
    del Canizo, Consuelo
    Guerci-Bresler, Agnes
    Nilsson, Lars
    Platzbecker, Uwe
    Luebbert, Michael
    Quesnel, Bruno
    Cazzola, Mario
    Ganser, Arnold
    Bowen, David
    Schlegelberger, Brigitte
    Aul, Carlo
    Knight, Robert
    Francis, John
    Fu, Tommy
    Hellstrom-Lindberg, Eva
    [J]. BLOOD, 2011, 118 (14) : 3765 - 3776
  • [8] CLINICAL BENEFIT OF LENALIDOMIDE TREATMENT FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME WITH DEL(5Q) BEFORE TRANSFUSION DEPENDENCE
    Oliva, E.
    Lauseker, M.
    Spiriti, M. A. Aloe
    Poloni, A.
    Cortelezzi, A.
    Palumbo, G.
    Balleari, E.
    Sanpaolo, G.
    Volpe, A.
    Ricco, A.
    Ronco, F.
    Alati, C.
    Santacaterina, I.
    Kuendgen, A.
    Germing, U.
    Latagliata, R.
    [J]. HAEMATOLOGICA, 2014, 99 : 517 - 517
  • [9] Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Cogle, Christopher
    Tinsley, Sara
    Sallman, David
    Lancet, Jeffrey E.
    Lis, Alan F.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 251 - 254
  • [10] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    A Kuendgen
    M Lauseker
    A F List
    P Fenaux
    A A Giagounidis
    N A Brandenburg
    J Backstrom
    A Glasmacher
    J Hasford
    U Germing
    [J]. Leukemia, 2013, 27 : 1072 - 1079
12345